Completed EARLY_PHASE1 INTERVENTIONAL 2-arm NCT00689416

Effects of Crestor on Inflammation of Atherosclerotic Plaques

Exploratory Study of New Imaging Biomarkers for Measurement of Carotid Plaque Inflammation

Sponsor: AstraZeneca

Conditions Atherosclerosis Inflammatory Activity in Carotid Arteries

Updated 6 times since 2017 Last updated: Jun 29, 2009 Started: Dec 31, 2007 Completion: Jun 30, 2009

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

A EARLY_PHASE1 clinical study on Atherosclerosis and Inflammatory Activity in Carotid Arteries, this trial is completed. The trial is conducted by AstraZeneca and has accumulated 6 data snapshots since 2007. Longitudinal tracking of this trial contributes to a broader understanding of treatment development timelines.

Status Flow

Change History

6 versions recorded

Sep 2024 — Present [monthly]

Completed EARLY_PHASE1
Jul 2024 — Sep 2024 [monthly]

Completed EARLY_PHASE1
Jan 2021 — Jul 2024 [monthly]

Completed EARLY_PHASE1
Jun 2018 — Jan 2021 [monthly]

Completed EARLY_PHASE1
Feb 2017 — Jun 2018 [monthly]

Completed EARLY_PHASE1

Phase: Phase 0 → EARLY_PHASE1

▶ Show 1 earlier version

Jan 2017 — Feb 2017 [monthly]

Completed Phase 0

First recorded

Dec 2007

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

AstraZeneca

Data source: AstraZeneca

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

• Uppsala, Sweden